1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

GLENMARK.BO
Glenmark Pharmaceuticals LimitedIN flagBombay Stock Exchange
2,270.45
INR
+60.60
- -
641.06BMarket Cap

Total Valuation

Glenmark Pharmaceuticals Limited carries a market capitalization of 641.06B, placing it among publicly traded companies globally. Its enterprise value stands at 594.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap641.06B
Enterprise Value594.00B

Share Statistics

Glenmark Pharmaceuticals Limited currently has 282.20M shares outstanding.

Shares Outstanding282.20M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Glenmark Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 44.21. The price-to-sales ratio is 3.60, and the price-to-book ratio stands at 2,133.53.

PE Ratio44.21
PS Ratio3.60
PB Ratio2,133.53
P/TBV Ratio7.52
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Glenmark Pharmaceuticals Limited trades at an EV/EBITDA multiple of 14.85 and an EV/FCF ratio of 414.72. The EV/Sales ratio of 3.55 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.85 provides insight into valuation relative to core operating earnings.

EV / Sales3.55
EV / EBITDA14.85
EV / EBIT14.85
EV / FCF414.72

Financial Position

Glenmark Pharmaceuticals Limited maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.65, indicating elevated leverage, while an interest coverage ratio of 19.16 demonstrates strong ability to service its debt obligations.

Current Ratio1.77
Quick Ratio0.22
Debt / Equity5.65
Debt / EBITDA0.15
Interest Coverage19.16

Financial Efficiency

Glenmark Pharmaceuticals Limited posts a return on equity of 30.76 and a return on invested capital of 24.48.

Return on Equity (ROE)30.76
Return on Assets (ROA)7.57
Return on Invested Capital (ROIC)24.48
Return on Capital Employed (ROCE)25.25
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.47

Taxes

Over the trailing twelve months, Glenmark Pharmaceuticals Limited has paid 6.23B in income taxes, reflecting an effective tax rate of 31.38.

Income Tax6.23B
Effective Tax Rate31.38

Stock Price Statistics

Glenmark Pharmaceuticals Limited's stock has gained approximately 21.91317% over the past 52 weeks. The 50-day moving average sits at 2,263.75, while the 200-day moving average is 2,073.80.

Beta (5Y)N/A
52-Week Price Change21.91317%
50-Day Moving Average2,263.75
200-Day Moving Average2,073.80
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Glenmark Pharmaceuticals Limited generated 167.11B in revenue and converted that into 13.62B in net income, yielding earnings per share of 48.24. EBITDA reached 39.99B, while operating income came in at 39.99B.

Revenue167.11B
Gross Profit119.64B
Operating Income39.99B
Pretax Income19.85B
Net Income13.62B
EBITDA39.99B
EBIT39.99B
Earnings Per Share (EPS)48.24

Balance Sheet

Glenmark Pharmaceuticals Limited holds 14.01B in cash and equivalents against 5.94B in total debt, resulting in a net debt position of -11.75B. Total book value stands at 282.20M, with working capital of 49.23B providing operational flexibility.

Cash & Cash Equivalents14.01B
Total Debt5.94B
Net Debt-11.75B
Equity (Book Value)282.20M
Book Value Per Share1.00
Working Capital49.23B

Margins

Glenmark Pharmaceuticals Limited operates with a gross margin of 71.59, reflecting its pricing power and cost economics. The operating margin of 23.93 and net profit margin of 8.15 provide insight into operational efficiency.

Gross Margin71.59
Operating Margin23.93
Pretax Margin11.88
Profit Margin8.15
EBITDA Margin23.93

Stock Splits

Glenmark Pharmaceuticals Limited's most recent stock split took place on September 10, 2007 with a 1:2 split ratio.

Last Split Date9/10/2007
Split Ratio1:2

Scores

Glenmark Pharmaceuticals Limited posts an Altman Z-Score of 5.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.90